UNSPSC 51161528: Acitazanolast

This classification denotes an anti-asthmatic agent with the molecular formula C9H7N5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 99Y8VJ356G, chemically known as oxanilic acid, 3-(1h-tetrazol-5-yl)- but generally known as acitazanolast, which bears US NIH Compound Identifier 2006. Acitazanolast comes in base and hydrate forms. European Medicines Agency schedules Acitazanolast in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05238MIG.

UNSPSC 51161528 Acitazanolast is a Commodity code capturing a single pharmaceutical product line. State and local governments procure this and related generic pharmaceuticals through multistate cooperative purchasing vehicles that consolidate demand across participating jurisdictions and member agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary active issuing body under this code. Solicitations seek manufacturers willing to supply through authorized wholesalers under fixed or competitive pricing structures, with contracts requiring compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintenance of chargeback-capable relationships with multiple authorized distributors, and comprehensive insurance including $5,000,000 commercial general liability. Vendors must provide detailed product specifications by National Drug Code, SKU, UPC, and dosage form, and accept performance penalties for late reporting or contract violations. Geographic scope extends across MMCAP member states including Minnesota and Oregon, with additional participating jurisdictions implied by the multistate structure.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, for multiple contracts supplying generic multi-source pharmaceuticals and over-the-counter products, with proposals due March 26, 2026. Evaluation weights heavily price competitiveness (75 percent) alongside compliance with administrative fee formats, electronic data interchange capability, and fixed pricing terms. Awarded vendors will distribute products through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contract terms of two years for new respondents and extensions through June 30, 2028 for incumbents. MMCAP reserves discretion over sole, dual, or multi-awards based on therapeutic and patient-safety factors. No specific set-aside or disadvantaged-business preferences are identified in the documentation.